Terms: = Leukemia AND ERBB4, MGC138404, 2066, ENSG00000178568, Q15303, p180erbB4, HER4
58 results:
1. erbb4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms.
Arribas AJ; Napoli S; Cascione L; Barnabei L; Sartori G; Cannas E; Gaudio E; Tarantelli C; Mensah AA; Spriano F; Zucchetto A; Rossi FM; Rinaldi A; Castro de Moura M; Jovic S; Bordone Pittau R; Stathis A; Stussi G; Gattei V; Brown JR; Esteller M; Zucca E; Rossi D; Bertoni F
Mol Cancer Ther; 2024 Mar; 23(3):368-380. PubMed ID: 38052765
[TBL] [Abstract] [Full Text] [Related]
2. Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract.
Wu H; Yu Z; Liu Y; Guo L; Teng L; Guo L; Liang L; Wang J; Gao J; Li R; Yang L; Nie X; Su D; Liang Z
Cancer Commun (Lond); 2022 Dec; 42(12):1367-1386. PubMed ID: 36264285
[TBL] [Abstract] [Full Text] [Related]
3. Neuregulin-1 promotes the proliferation, migration, and angiogenesis of human periodontal ligament stem cells in vitro.
Li L; Shang L; Kang W; Du L; Ge S
Cell Biol Int; 2022 May; 46(5):792-805. PubMed ID: 35077607
[TBL] [Abstract] [Full Text] [Related]
4. erbb4 and Multiple MicroRNAs That Target erbb4 Participate in Pregnancy-Related Cardiomyopathy.
Feyen E; Ricke-Hoch M; Van Fraeyenhove J; Vermeulen Z; Scherr M; Dugaucquier L; Viereck J; Bruyns T; Thum T; Segers VFM; Hilfiker-Kleiner D; De Keulenaer GW
Circ Heart Fail; 2021 Jul; 14(7):e006898. PubMed ID: 34247489
[TBL] [Abstract] [Full Text] [Related]
5. Detection of Gene Fusion Transcripts in Peripheral T-Cell Lymphoma Using a Multiplexed Targeted Sequencing Assay.
Drieux F; Ruminy P; Sater V; Marchand V; Fataccioli V; Lanic MD; Viennot M; Viailly PJ; Sako N; Robe C; Dupuy A; Vallois D; Veresezan L; Poullot E; Picquenot JM; Bossard C; Parrens M; Lemonnier F; Jardin F; de Leval L; Gaulard P
J Mol Diagn; 2021 Aug; 23(8):929-940. PubMed ID: 34147695
[TBL] [Abstract] [Full Text] [Related]
6. Development and application of high-throughput screens for the discovery of compounds that disrupt erbb4 signaling: Candidate cancer therapeutics.
Cullum RL; Lucas LM; Senfeld JI; Piazza JT; Neel LT; Whig K; Zhai L; Harris MH; Rael CC; Taylor DC; Cook LJ; Kaufmann DP; Mill CP; Jacobi MA; Smith FT; Suto M; Bostwick R; Gupta RB; David AE; Riese Ii DJ
PLoS One; 2020; 15(12):e0243901. PubMed ID: 33378376
[TBL] [Abstract] [Full Text] [Related]
7. mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.
Beauchamp RL; Erdin S; Witt L; Jordan JT; Plotkin SR; Gusella JF; Ramesh V
J Biol Chem; 2021; 296():100157. PubMed ID: 33273014
[TBL] [Abstract] [Full Text] [Related]
8. Megakaryocytes, erythropoietic and granulopoietic cells express CAL2 antibody in myeloproliferative neoplasms carrying CALR gene mutations.
Ali H; Puccio I; Akarca AU; Bob R; Pomplun S; Keong Wong W; Gupta R; Sekhar M; Lambert J; Al-Masri H; Stein H; Marafioti T
Int J Exp Pathol; 2021 Feb; 102(1):45-50. PubMed ID: 32929772
[TBL] [Abstract] [Full Text] [Related]
9. [Clinical Analysis of 66 Patients with Essential Thrombocytopenia].
Zhang LJ; Shi YY; Chen Y; Gan YM; Shi WT; Chen KK; Ding BH; He ZM; Wang CL; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1321-1325. PubMed ID: 32798420
[TBL] [Abstract] [Full Text] [Related]
10. Potent dual EGFR/her4 tyrosine kinase inhibitors containing novel (1,2-dithiolan-4-yl)acetamides.
Mansour TS; Pallepati RR; Basetti V
Bioorg Med Chem Lett; 2020 Aug; 30(16):127288. PubMed ID: 32631510
[TBL] [Abstract] [Full Text] [Related]
11. The role of endothelial autocrine NRG1/erbb4 signaling in cardiac remodeling.
Dugaucquier L; Feyen E; Mateiu L; Bruyns TAM; De Keulenaer GW; Segers VFM
Am J Physiol Heart Circ Physiol; 2020 Aug; 319(2):H443-H455. PubMed ID: 32618511
[TBL] [Abstract] [Full Text] [Related]
12. Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1-KMT2A-YAP1 and VIM-KMT2A fusions.
Massoth LR; Hung YP; Nardi V; Nielsen GP; Hasserjian RP; Louissaint A; Fisch AS; Deshpande V; Zukerberg LR; Lennerz JK; Selig M; Glomski K; Patel PJ; Williams KJ; Sokol ES; Alexander BM; Vergilio JA; Ross JS; Pavlick DC; Chebib I; Williams EA
Mod Pathol; 2020 Nov; 33(11):2307-2317. PubMed ID: 32461620
[TBL] [Abstract] [Full Text] [Related]
13. Mechanisms of the Multitasking Endothelial Protein NRG-1 as a Compensatory Factor During Chronic Heart Failure.
De Keulenaer GW; Feyen E; Dugaucquier L; Shakeri H; Shchendrygina A; Belenkov YN; Brink M; Vermeulen Z; Segers VFM
Circ Heart Fail; 2019 Oct; 12(10):e006288. PubMed ID: 31607147
[TBL] [Abstract] [Full Text] [Related]
14. Challenges in next generation sequencing analysis of somatic mutations in transplant patients.
Chen H; Luthra R; Patel KP; Routbort M; Rashid A; Roy-Chowdhuri S; Lazar A; Broaddus R; Manekia J; Singh RR; Yemelyanova A
Cancer Genet; 2018 Oct; 226-227():17-22. PubMed ID: 30005850
[TBL] [Abstract] [Full Text] [Related]
15. An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute leukemia.
Shouval R; Ruggeri A; Labopin M; Mohty M; Sanz G; Michel G; Kuball J; Chevallier P; Al-Seraihy A; Milpied NJ; de Heredia CD; Arcese W; Blaise D; Rocha V; Fein J; Unger R; Baron F; Bader P; Gluckman E; Nagler A
Clin Cancer Res; 2017 Nov; 23(21):6478-6486. PubMed ID: 28754820
[No Abstract] [Full Text] [Related]
16. [Research progress of neuregulin 4 biological function].
Yang F; Li XN
Sheng Li Xue Bao; 2017 Jun; 69(3):351-356. PubMed ID: 28638929
[TBL] [Abstract] [Full Text] [Related]
17. The Total Body Irradiation Schedule Affects Acute leukemia Relapse After Matched T Cell-Depleted Hematopoietic Stem Cell Transplantation.
Aristei C; Carotti A; Palazzari E; Amico L; Ruggeri L; Perrucci E; Falcinelli L; Lancellotta V; Palumbo I; Falzetti F; Aversa F; Merluzzi M; Velardi A; Martelli MF
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(4):832-839. PubMed ID: 27623308
[TBL] [Abstract] [Full Text] [Related]
18. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.
Maurea N; Coppola C; Piscopo G; Galletta F; Riccio G; Esposito E; De Lorenzo C; De Laurentiis M; Spallarossa P; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e19-e26. PubMed ID: 27755239
[TBL] [Abstract] [Full Text] [Related]
19. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.
Maurea N; Coppola C; Piscopo G; Galletta F; Riccio G; Esposito E; De Lorenzo C; De Laurentiis M; Spallarossa P; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S19-26. PubMed ID: 27183521
[TBL] [Abstract] [Full Text] [Related]
20. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
[TBL] [Abstract] [Full Text] [Related]
[Next]
